Further aspects of doxycycline therapy in COVID-19.

Abstract

Dermatologic TherapyVolume 33, Issue 6 e13810 LETTER Further aspects of doxycycline therapy in COVID-19 Győző Szolnoky, Corresponding Author Győző Szolnoky szolnokygyozo@gmail.com orcid.org/0000-0002-5391-4426 Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary Correspondence Győző Szolnoky, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary, Korányi fasor 6, H-6720 Szeged, Hungary. Email: szolnokygyozo@gmail.comSearch for more papers by this author Győző Szolnoky, Corresponding Author Győző Szolnoky szolnokygyozo@gmail.com orcid.org/0000-0002-5391-4426 Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary Correspondence Győző Szolnoky, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary, Korányi fasor 6, H-6720 Szeged, Hungary. Email: szolnokygyozo@gmail.comSearch for more papers by this author First published: 13 June 2020 https://doi.org/10.1111/dth.13810Citations: 7Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume33, Issue6November/December 2020e13810 RelatedInformation